Literature DB >> 3029759

Production of glycosylated physiologically "normal" human alpha 1-antitrypsin by mouse fibroblasts modified by insertion of a human alpha 1-antitrypsin cDNA using a retroviral vector.

R I Garver, A Chytil, S Karlsson, G A Fells, M L Brantly, M Courtney, P W Kantoff, A W Nienhuis, W F Anderson, R G Crystal.   

Abstract

Alpha 1-Antitrypsin (alpha 1AT) deficiency is a hereditary disorder characterized by reduced serum levels of alpha 1AT, resulting in destruction of the lower respiratory tract by neutrophil elastase. As an approach to augment alpha 1AT levels in this disorder with physiologically normal human alpha 1AT, we have integrated a full-length normal human alpha 1AT cDNA into the genome of mouse fibroblasts. To accomplish this, the retroviral vector N2 was modified by inserting the simian virus 40 early promoter followed by the alpha 1AT cDNA. Southern analysis demonstrated that the intact cDNA was present in the genome of selected clones of the transfected murine fibroblasts psi 2 and infected NIH 3T3. The clones produced three mRNA transcripts (5.8, 4.8, and 2.4 kilobases) containing human alpha 1AT sequences, secreted an alpha 1AT molecule recognized by an anti-human alpha 1AT antibody, with the same molecular mass (52 kDa) as normal human alpha 1AT and that complexed with and inhibited human neutrophil elastase. The psi 2 produced alpha 1AT was glycosylated, and when infused intravenously into mice, it had a serum half-life similar to normal alpha 1AT purified from human plasma and markedly longer than that of nonglycosylated human alpha 1AT cDNA-directed yeast-produced alpha 1AT. These studies demonstrate the feasibility of using a retroviral vector to insert the normal human alpha 1AT cDNA into non-alpha 1AT-producing cells, resulting in the synthesis and secretion of physiologically "normal" human alpha 1AT.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3029759      PMCID: PMC304359          DOI: 10.1073/pnas.84.4.1050

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

Review 1.  The Pi polymorphism: genetic, biochemical, and clinical aspects of human alpha 1-antitrypsin.

Authors:  M K Fagerhol; D W Cox
Journal:  Adv Hum Genet       Date:  1981

Review 2.  Human plasma proteinase inhibitors.

Authors:  J Travis; G S Salvesen
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

Review 3.  Form and function of retroviral proviruses.

Authors:  H E Varmus
Journal:  Science       Date:  1982-05-21       Impact factor: 47.728

Review 4.  Synthesis and processing of asparagine-linked oligosaccharides.

Authors:  S C Hubbard; R J Ivatt
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

Review 5.  Alpha1-antitrypsin and its deficiency.

Authors:  F Kueppers; L F Black
Journal:  Am Rev Respir Dis       Date:  1974-08

6.  Deletions covering the putative promoter region of early mRNAs of simian virus 40 do not abolish T-antigen expression.

Authors:  C Benoist; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

7.  Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema.

Authors:  J E Gadek; G A Fells; R L Zimmerman; S I Rennard; R G Crystal
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

8.  Studies on the oligosaccharide chains of human alpha 1-protease inhibitor. II. Structure of oligosaccharides.

Authors:  T Mega; E Lujan; A Yoshida
Journal:  J Biol Chem       Date:  1980-05-10       Impact factor: 5.157

9.  Expression of the alpha-1-antitrypsin gene in mononuclear phagocytes of normal and alpha-1-antitrypsin-deficient individuals.

Authors:  J F Mornex; A Chytil-Weir; Y Martinet; M Courtney; J P LeCocq; R G Crystal
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

10.  Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects.

Authors:  J E Gadek; H G Klein; P V Holland; R G Crystal
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

View more
  16 in total

Review 1.  Prospects for homologous recombination in human gene therapy.

Authors:  M A Vega
Journal:  Hum Genet       Date:  1991-07       Impact factor: 4.132

2.  Alpha 1-antitrypsin deficiency caused by the alpha 1-antitrypsin Nullmattawa gene. An insertion mutation rendering the alpha 1-antitrypsin gene incapable of producing alpha 1-antitrypsin.

Authors:  D Curiel; M Brantly; E Curiel; L Stier; R G Crystal
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

Review 3.  Adenovirus: the first effective in vivo gene delivery vector.

Authors:  Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2014-01       Impact factor: 5.695

4.  Oncostatin M and TNF-α Induce Alpha-1 Antitrypsin Production in Undifferentiated Adipose Stromal Cells.

Authors:  Kevin Ni; Muhammad Umair Mukhtar Mian; Catherine Meador; Amar Gill; Daria Barwinska; Danting Cao; Matthew J Justice; Di Jiang; Niccolette Schaefer; Kelly S Schweitzer; Hong Wei Chu; Keith L March; Irina Petrache
Journal:  Stem Cells Dev       Date:  2017-09-21       Impact factor: 3.272

5.  High-level expression of biologically active human alpha 1-antitrypsin in the milk of transgenic mice.

Authors:  A L Archibald; M McClenaghan; V Hornsey; J P Simons; A J Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

6.  Site-specific enzymatic polysialylation of therapeutic proteins using bacterial enzymes.

Authors:  Theresa Lindhout; Umar Iqbal; Lisa M Willis; Anne N Reid; Jianjun Li; Xin Liu; Maria Moreno; Warren W Wakarchuk
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

7.  Approaches to maximizing stable expression of alpha 1-antitrypsin in transformed CHO cells.

Authors:  T Paterson; J Innes; S Moore
Journal:  Appl Microbiol Biotechnol       Date:  1994-01       Impact factor: 4.813

8.  Improvement of avian leukosis virus (ALV)-based retrovirus vectors by using different cis-acting sequences from ALVs.

Authors:  F L Cosset; C Legras; J L Thomas; R M Molina; Y Chebloune; C Faure; V M Nigon; G Verdier
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

9.  An alternative approach to somatic cell gene therapy.

Authors:  D St Louis; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

Review 10.  Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy.

Authors:  Joanna Wozniak; Tomasz Wandtke; Piotr Kopinski; Joanna Chorostowska-Wynimko
Journal:  Hum Gene Ther       Date:  2015-09-29       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.